GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » EBIT

Abaxis (Abaxis) EBIT : $38.7 Mil (TTM As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis EBIT?

Abaxis's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2018 was $12.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2018 was $38.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Abaxis's annualized ROC % for the quarter that ended in Mar. 2018 was 24.81%. Abaxis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was 57.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Abaxis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2018 was 2.04%.


Abaxis EBIT Historical Data

The historical data trend for Abaxis's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis EBIT Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.23 34.30 46.35 44.49 38.66

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.16 8.46 9.44 8.58 12.18

Competitive Comparison of Abaxis's EBIT

For the Diagnostics & Research subindustry, Abaxis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abaxis's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abaxis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abaxis's EV-to-EBIT falls into.



Abaxis EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abaxis  (NAS:ABAX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Abaxis's annualized ROC % for the quarter that ended in Mar. 2018 is calculated as:

ROC % (Q: Mar. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2017 ) + Invested Capital (Q: Mar. 2018 ))/ count )
=48.728 * ( 1 - 28.25% )/( (148.279 + 133.575)/ 2 )
=34.96234/140.927
=24.81 %

where

Invested Capital(Q: Dec. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=338.763 - 28.865 - ( 161.619 - max(0, 42.383 - 250.803+161.619))
=148.279

Invested Capital(Q: Mar. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=341.103 - 40.745 - ( 166.783 - max(0, 43.88 - 264.248+166.783))
=133.575

Note: The Operating Income data used here is four times the quarterly (Mar. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Abaxis's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2017  Q: Mar. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=48.728/( ( (34.902 + max(46.801, 0)) + (35.419 + max(53.585, 0)) )/ 2 )
=48.728/( ( 81.703 + 89.004 )/ 2 )
=48.728/85.3535
=57.09 %

where Working Capital is:

Working Capital(Q: Dec. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.391 + 42.498 + 6.295) - (28.865 + 1.054 + 12.464)
=46.801

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48.164 + 44.121 + 5.18) - (40.745 + 0.816 + 2.319)
=53.585

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Abaxis's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2018 )
=38.655/1898.290
=2.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abaxis EBIT Related Terms

Thank you for viewing the detailed overview of Abaxis's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Abaxis (Abaxis) Business Description

Traded in Other Exchanges
N/A
Address
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020